Case Study: Compass Pathways

Human ADME Clinical Trial Design for Psychedelics: A Case Study with Compass Pathways

Compass Pathways is at the forefront of developing innovative mental health treatments, including their investigational proprietary synthetic crystalline psilocybin formulation, COMP360. 

As a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, Compass Pathways is pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. 

To advance COMP360 towards regulatory approval, Compass Pathways partnered with Quotient Sciences to conduct a human ADME study to understand how COMP360 is absorbed, distributed, metabolised, and excreted in the human body.

Request a copy of our case study with Compass Pathways today to find out more about how COMP360 was successfully administered to healthy volunteers in a controlled clinical setting.